Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Phathom Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Phathom Pharmaceuticals, Inc.

PHAT

Phathom Pharmaceuticals, Inc.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals develops and commercializes novel gastrointestinal treatments, primarily focusing on vonoprazan, a potent, fast-acting potassium-competitive acid blocker. Its core products target acid-related GI diseases such as GERD and H. pylori infection. The company emphasizes innovative therapies with improved efficacy over traditional PPIs, leveraging a differentiated mechanism of action, and aims to expand indications and formulations in the U.S. and international markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Phathom Pharmaceuticals, Inc.

1
1
Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals Reports 104% Revenue Growth to $58.3 Million in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals Reports $175.1 Million in Product Revenues for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals Reports $49.5M Revenue in Q3 2025, Net Loss Improves

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals Reports $39.5M Product Revenue in Q2 2025, Faces $75.8M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals Reports $28.5M Revenue Growth Amid $94.3M Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals Reports $334.3 Million Net Loss for 2024 Amid Commercial Launch of VOQUEZNA

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals Reports Revenue Growth, Net Loss in Q3 2024, Amid Strategic Progress and Financial Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments